178 related articles for article (PubMed ID: 28759518)
21. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
[TBL] [Abstract][Full Text] [Related]
22. Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.
Lee CL; Wahnishe H; Sayre GA; Cho HM; Kim HJ; Hernandez-Pampaloni M; Hawkins RA; Dannoon SF; VanBrocklin HF; Itsara M; Weiss WA; Yang X; Haas-Kogan DA; Matthay KK; Seo Y
Med Phys; 2010 Sep; 37(9):4861-7. PubMed ID: 20964203
[TBL] [Abstract][Full Text] [Related]
23. Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma.
Gaze MN; Gains JE; Walker C; Bomanji JB
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):66-78. PubMed ID: 23474636
[TBL] [Abstract][Full Text] [Related]
24. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
25. Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit.
Tristam M; Alaamer AS; Fleming JS; Lewington VJ; Zivanovic MA
J Nucl Med; 1996 Jun; 37(6):1058-63. PubMed ID: 8683301
[TBL] [Abstract][Full Text] [Related]
26. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy.
Markelewicz RJ; Lorenzen WA; Shusterman S; Grant FD; Fahey FH; Treves ST
Clin Nucl Med; 2013 Aug; 38(8):604-7. PubMed ID: 23797228
[TBL] [Abstract][Full Text] [Related]
27. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
28. Biodistribution of post-therapeutic versus diagnostic (131)I-MIBG scans in children with neuroblastoma.
Hickeson MP; Charron M; Maris JM; Brophy P; Kang TI; Zhuang H; Khan J; Nevrotski T
Pediatr Blood Cancer; 2004 Mar; 42(3):268-74. PubMed ID: 14752865
[TBL] [Abstract][Full Text] [Related]
29. Neuroblastoma: dose-related sensitivity of MIBG scanning in detection.
Parisi MT; Matthay KK; Huberty JP; Hattner RS
Radiology; 1992 Aug; 184(2):463-7. PubMed ID: 1620849
[TBL] [Abstract][Full Text] [Related]
30. Discrepant salivary gland response after radioiodine and MIBG therapies.
Jentzen W; Richter M; Poeppel TD; Schmitz J; Brandau W; Bockisch A; Binse I
Q J Nucl Med Mol Imaging; 2017 Sep; 61(3):331-339. PubMed ID: 25566809
[TBL] [Abstract][Full Text] [Related]
31. High-dose
Kayano D; Wakabayashi H; Nakajima K; Kuroda R; Watanabe S; Inaki A; Toratani A; Akatani N; Yamase T; Kunita Y; Hiromasa T; Takata A; Mori H; Saito S; Araki R; Taki J; Kinuya S
Ann Nucl Med; 2020 Jun; 34(6):397-406. PubMed ID: 32219730
[TBL] [Abstract][Full Text] [Related]
32. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
[TBL] [Abstract][Full Text] [Related]
33. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography.
Ott RJ; Tait D; Flower MA; Babich JW; Lambrecht RM
Br J Radiol; 1992 Sep; 65(777):787-91. PubMed ID: 1393416
[TBL] [Abstract][Full Text] [Related]
34. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
35. Comparison of [123I]MIBG and [131I]MIBG for imaging of neuroblastoma and other neural crest tumors.
Liu B; Zhuang H; Servaes S
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):21-8. PubMed ID: 23474632
[TBL] [Abstract][Full Text] [Related]
36. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
[TBL] [Abstract][Full Text] [Related]
37. Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results.
Buckley SE; Saran FH; Gaze MN; Chittenden S; Partridge M; Lancaster D; Pearson A; Flux GD
Cancer Biother Radiopharm; 2007 Feb; 22(1):105-12. PubMed ID: 17627418
[TBL] [Abstract][Full Text] [Related]
38. Radiopharmacokinetics and radiation absorbed dose calculations from 131I-meta-iodobenzylguanidine (131I-MIBG).
Ertl S; Deckart H; Blottner A; Tautz M
Nucl Med Commun; 1987 Aug; 8(8):643-53. PubMed ID: 3122135
[TBL] [Abstract][Full Text] [Related]
39. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.
Makris NE; Boellaard R; van Lingen A; Lammertsma AA; van Dongen GA; Verheul HM; Menke CW; Huisman MC
J Nucl Med; 2015 Feb; 56(2):249-54. PubMed ID: 25613538
[TBL] [Abstract][Full Text] [Related]
40. Biodistribution and Dosimetry of Indigenously Produced
Adnan A; Deep K; Kameswaran M; Nikam D; Shanmukaih C; Dash A; Banerjee S; Basu S
J Nucl Med Technol; 2019 Dec; 47(4):292-299. PubMed ID: 30413603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
